Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Six-Month Clinical Status as a Predictor of 24-Month Clinical Outcome in First-Admission Patients with Schizophrenia

Six-Month Clinical Status as a Predictor of 24-Month Clinical Outcome in First-Admission Patients... The aim of this study was to determine whether clinical status at 6-month follow-up is a predictor of 2-year clinical status in first-admission schizophrenic patients. If short-term status is indeed a strong predictor of subsequent functioning, the relationship would support earlier initiation of aggressive interventions. An epidemiologically based sample of 162 first-admission schizophrenic patients was examined at index hospitalization and at 6- and 24-month follow-up, using a variety of diagnostic and clinical assessment instruments. Respondents were divided into three groups based on their 6-month clinical status: delusions or hallucinations present at 6-month follow-up with or without negative symptoms (n = 63); moderate to high levels of negative symptoms (but not positive symptoms) present (n = 42); neither positive nor negative symptoms present (n = 57). Differences in 24-month clinical functioning were evaluated (GAF scores, BPRS factors, role functioning, number of rehospitalizations, and illness course). No significant differences were found among the three groups on demographic characteristics, substance abuse history, or extent of treatment during the follow-up. At 24-month follow-up, respondents with positive psychotic symptoms at 6-month follow-up had the worst, and those with no positive or negative symptoms the best functioning, with the negative-symptom group intermediate on most indices. Thus, among schizophrenic patients, poor 6-month clinical status identified a patient subgroup at high risk for continued poor clinical status at 24 months, suggesting the need for earlier intensive intervention in an attempt to prevent this progression. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Six-Month Clinical Status as a Predictor of 24-Month Clinical Outcome in First-Admission Patients with Schizophrenia

Download PDF
7 pages

Loading next page...
 
/lp/springer-journals/six-month-clinical-status-as-a-predictor-of-24-month-clinical-outcome-p2fFv270Q8
Publisher
Springer Journals
Copyright
Copyright © 1999 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1022357312048
Publisher site
See Article on Publisher Site

Abstract

The aim of this study was to determine whether clinical status at 6-month follow-up is a predictor of 2-year clinical status in first-admission schizophrenic patients. If short-term status is indeed a strong predictor of subsequent functioning, the relationship would support earlier initiation of aggressive interventions. An epidemiologically based sample of 162 first-admission schizophrenic patients was examined at index hospitalization and at 6- and 24-month follow-up, using a variety of diagnostic and clinical assessment instruments. Respondents were divided into three groups based on their 6-month clinical status: delusions or hallucinations present at 6-month follow-up with or without negative symptoms (n = 63); moderate to high levels of negative symptoms (but not positive symptoms) present (n = 42); neither positive nor negative symptoms present (n = 57). Differences in 24-month clinical functioning were evaluated (GAF scores, BPRS factors, role functioning, number of rehospitalizations, and illness course). No significant differences were found among the three groups on demographic characteristics, substance abuse history, or extent of treatment during the follow-up. At 24-month follow-up, respondents with positive psychotic symptoms at 6-month follow-up had the worst, and those with no positive or negative symptoms the best functioning, with the negative-symptom group intermediate on most indices. Thus, among schizophrenic patients, poor 6-month clinical status identified a patient subgroup at high risk for continued poor clinical status at 24 months, suggesting the need for earlier intensive intervention in an attempt to prevent this progression.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Sep 30, 2004

References

  • Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine
    Kane, J; Honigfeld, G; Singer, J; Meltzer, H
  • Risperidone in the treatment of schizophrenia
    Marder, SR; Meibach, RC
  • Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome
    Lieberman, JA; Safferman, AZ; Pollack, S; Szymanski, S; Johns, C; Howard, A; Kronig, M; Bookstein, P; Kane, JM
  • Patient response and resource management: another view of clozapine treatment of schizophrenia
    Carpenter, WT; Conley, RR; Buchanan, RW; Breier, A; Tamminga, CA
  • Treatment strategies for schizophrenia
    Ereshefsky, L
  • Psychotherapy of schizophrenia revisited
    Wasylenki, DA
  • Assertive community treatment: an update of randomized trials
    Burns, BJ; Santos, AB
  • Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia
    Meltzer, HY; Cola, P; Way, L; Thompson, PA; Bastani, B; Davies, MA; Snitz, B
  • Cost-effectiveness of clozapine therapy for severe psychosis
    Ghaemi, SN; Ziegler, DM; Peachey, TJ; Goodwin, FK
  • A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia
    Rosenheck, R; Cramer, J; Xu, W; Thomas, J; Henderson, W; Frisman, L; Fye, C; Charney, D
  • Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy—-a retrospective analysis using the Saskatchewan Health Linkable Databases
    Albright, PS; Livingstone, S; Keegan, DL; Ingham, M; Shrikhande, S; LeLorier, J
  • Risperidone versus haloperidol: II. cost-effectiveness
    Davies, A; Langley, PC; Keks, NA; Catts, SV; Lambert, T; Schweitzer, I
  • Who should receive clozapine?
    Marder, SR; Van Putten, T
  • Defining managed care in public sector psychiatry
    Hoge, MA; Davidson, L; Griffith, EE; Sledge, WH; Howenstine, RA
  • Characteristics of private-sector managed care for mental health and substance abuse treatment
    Garnick, DW; Hendricks, AM; Dulski, JD; Thorpe, KE; Horgan, C
  • Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia
    Breier, A; Buchanan, RW; Kirkpatrick, B; Davis, OR; Irish, D; Summerfelt, A; Carpenter, WT
  • Premorbid and clinical predictors of short-term course in first-admission psychotic patients: Preliminary results
    Bromet, EJ; Jandorf, L; Fennig, S; Lavelle, J; Kovasznay, B; Ram, R; Tanenberg-Karant, M; Craig, T
  • The Structured Clinical Interview for DSM-III-R (SCID) I: history, rationale and description
    Spitzer, RL; Williams, J; Gibbon, M; First, MB
  • Six-month stability of psychiatric diagnosis in first admission patients with psychosis
    Fennig, S; Kovasznay, B; Rich, C; Ram, R; Pato, C; Miller, A; Rubinstein, J; Carlson, G; Schwartz, JE; Phelan, J; Lavelle, J; Craig, T; Bromet, E
  • Symptoms of schizophrenia: methods, meanings, and mechanisms
    Andreasen, NC; Arndt, S; Alliger, R; Miller, D; Flaum, M
  • Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study
    Jablensky, A; Sartorius, N; Ernberg, G; Anker, M; Korten, A; Cooper, JE; Day, R; Bertelsen, A
  • Anchoring the BPRS: an aid to improved reliability
    Woerner, MG; Mannuzza, S; Kane, JM
  • The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome
    Heinrichs, DW; Hanlon, TE; Carpenter, WT
  • European versus United States data on the course of schizophrenia
    Marengo, J; Harrow, M; Sands, J; Galloway, C
  • One hundred years of schizophrenia: a meta-analysis of the outcome literature
    Hegarty, JD; Baldessarini, RJ; Tohen, M; Waternaux, C; Oepen, G
  • The natural course of schizophrenia: a review of first-admission studies
    Ram, R; Bromet, EJ; Eaton, WW; Pato, C; Schwartz, JE
  • A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
    Chouinard, G; Jones, B; Remington, G; Bloom, D; Addington, D; MacEwan, GW; Labelle, A; Beauclair, L; Arnott, W
  • Risperidone in the treatment of schizophrenia
    Marder, SR; Meibach, RC.
  • Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol
    Peuskens, J.
  • Characteristics of very poor outcome schizophrenia
    Keefe, RSE; Mohs, RC; Losonczy, MF; Davidson, M; Silverman, JM; Kendler, KS; Horvath, TB; Nora, R; Davis, KL
  • Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia
    Wolkin, A; Barouche, F; Wolf, AP; Rotrosen, J; Fowler, JS; Shiue, CY; Cooper, TB; Brodie, JD
  • Are there more than two syndromes in schizophrenia? a critique of the positive-negative dichotomy
    Peralta, V; de Leon, J; Cuesta, MJ
  • Cerebellar atrophy in schizophrenia and affective disorder
    Yates, WR; Jacoby, CG; Andreasen, NC
  • Specific and non-specific effects of educational intervention with families living with a schizophrenic relative
    Smith, JV; Birchwood, MJ
  • Schizophrenic syndromes, cognitive performance and neurological dysfunction
    Liddle, PF
  • The National Institute of Mental Health longitudinal study of chronic schizophrenia
    Breier, A; Schreiber, JL; Dyer, J; Pickar, D
  • Is modern-day schizophrenia outcome still negative?
    Harrow, M; Grinker, RR; Silverstein, ML; Holzman, P
  • Time course and biologic correlates of treatment response in first-episode schizophrenia
    Lieberman, J; Jody, D; Geisler, S; Alvir, J; Loebel, A; Szymanski, S; Woerner, M; Borenstein, M
  • Translating treatment research findings into clinical action [editorial]
    Schooler, NR
  • Chronicity in schizophrenia: fact, partial fact, or artifact?
    Harding, CM; Zubin, J; Strauss, JS